{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:24:39Z","timestamp":1792783479262,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T00:00:00Z","timestamp":1756252800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T00:00:00Z","timestamp":1756252800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Eva Vilarrasa"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s13555-025-01521-z","type":"journal-article","created":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T15:34:35Z","timestamp":1756308875000},"page":"3267-3283","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Long-Term Effectiveness and Safety of Bimekizumab in Patients with Moderate to Severe Hidradenitis Suppurativa Under Real Clinical Practice Conditions: The Importance of Combined Treatment in Hurley\u00a0III Patients and Potential Factors Associated with Complete Response"],"prefix":"10.1007","volume":"15","author":[{"given":"Miguel","family":"Mansilla-Polo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Garc\u00eda-Moronta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Fern\u00e1ndez-Crehuet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Garbayo-Salmons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mart\u00ed","family":"Pons-Benavent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc\u00eda","family":"Aguilar-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Jim\u00e9nez-Gallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebeca","family":"Alcal\u00e1-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma","family":"Mart\u00edn-Ezquerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Martorell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Mahiques-Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Alfageme-Rold\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bego\u00f1a","family":"Escutia-Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Sahuquillo-Torralba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Fayos-Gregori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Soto-Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"S\u00e1nchez-Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Botella-Estrada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6507-0534","authenticated-orcid":false,"given":"Eva","family":"Vilarrasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6882-2113","authenticated-orcid":false,"given":"Alejandro","family":"Molina-Leyva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the Spanish Hidradenitis Suppurativa Group (GEHS)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,27]]},"reference":[{"key":"1521_CR1","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.ad.2015.06.004","volume":"106","author":"A Martorell","year":"2015","unstructured":"Martorell A, Garc\u00eda-Mart\u00ednez FJ, Jim\u00e9nez-Gallo D, et al. An update on hidradenitis suppurativa (part I): epidemiology, clinical aspects, and definition of disease severity. Actas Dermo-Sifiliograficas. 2015;106:703\u201315.","journal-title":"Actas Dermo-Sifiliograficas"},{"key":"1521_CR2","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.ad.2023.05.015","volume":"114","author":"M Mansilla-Polo","year":"2023","unstructured":"Mansilla-Polo M, Escutia-Mu\u00f1oz B, Botella-Estrada R. Narrative review and update on biologic and small molecule drugs for hidradenitis suppurativa: an entity with a promising future. Actas Dermosifiliogr. 2023;114:772\u201383.","journal-title":"Actas Dermosifiliogr"},{"key":"1521_CR3","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1111\/ijd.17569","volume":"64","author":"SE Marron","year":"2025","unstructured":"Marron SE, Gracia-Caza\u00f1a T, Sampogna F, et al. Stigmatization and perceived health status in patients with hidradenitis suppurativa: an observational multicenter study in Europe. Int J Dermatol. 2025;64:861\u20139.","journal-title":"Int J Dermatol"},{"key":"1521_CR4","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/j.jaad.2019.08.090","volume":"82","author":"SR Goldburg","year":"2020","unstructured":"Goldburg SR, Strober BE, Payette MJ. Hidradenitis suppurativa: epidemiology, clinical presentation, and pathogenesis. J Am Acad Dermatol. 2020;82:1045\u201358.","journal-title":"J Am Acad Dermatol"},{"key":"1521_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02965","volume":"9","author":"ARJV Vossen","year":"2018","unstructured":"Vossen ARJV, van der Zee HH, Prens EP. Hidradenitis suppurativa: a systematic review integrating inflammatory pathways into a cohesive pathogenic model. Front Immunol. 2018;9:2965.","journal-title":"Front Immunol"},{"key":"1521_CR6","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/cei.13449","volume":"201","author":"JM Fletcher","year":"2020","unstructured":"Fletcher JM, Moran B, Petrasca A, Smith CM. IL-17 in inflammatory skin diseases psoriasis and hidradenitis suppurativa. Clin Exp Immunol. 2020;201:121\u201334.","journal-title":"Clin Exp Immunol"},{"key":"1521_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11010127","volume":"11","author":"O Somogyi","year":"2023","unstructured":"Somogyi O, Dajnoki Z, Szab\u00f3 L, et al. New data on the features of skin barrier in hidradenitis suppurativa. Biomedicines. 2023;11:127.","journal-title":"Biomedicines"},{"key":"1521_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01894","volume":"11","author":"R Adams","year":"2020","unstructured":"Adams R, Maroof A, Baker T, et al. Bimekizumab, a novel humanized IgG1 antibody that neutralizes both IL-17A and IL-17F. Front Immunol. 2020;11:1894.","journal-title":"Front Immunol"},{"key":"1521_CR9","unstructured":"Bimzelx\u00ae (bimekizumab) SmPC. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/bimzelx-epar-product-information_en.pdf. Accessed 27 May 2025."},{"key":"1521_CR10","unstructured":"Cosentyx\u00ae (secukinumab) SmPC. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/secukinumab-epar-product-information_en.pdf. Accessed 27 May 2025."},{"issue":"e139932","key":"1521_CR11","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.139932","volume":"5","author":"MM Lowe","year":"2020","unstructured":"Lowe MM, Naik HB, Clancy S, et al. Immunopathogenesis of hidradenitis suppurativa and response to anti-TNF-\u03b1 therapy. JCI Insight. 2020;5(e139932):139932.","journal-title":"JCI Insight"},{"key":"1521_CR12","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1016\/S0140-6736(24)00101-6","volume":"403","author":"AB Kimball","year":"2024","unstructured":"Kimball AB, Jemec GBE, Sayed CJ, et al. Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase\u00a03 trials. Lancet. 2024;403:2504\u201319.","journal-title":"Lancet"},{"key":"1521_CR13","doi-asserted-by":"publisher","first-page":"e198","DOI":"10.1111\/ajd.14339","volume":"65","author":"M Mansilla-Polo","year":"2024","unstructured":"Mansilla-Polo M, Pons-Benavent M, Fern\u00e1ndez-Crehuet P, et al. Real-world effectiveness and safety of bimekizumab for hidradenitis suppurativa: an ambispective observational study. Australas J Dermatol. 2024;65:e198-202.","journal-title":"Australas J Dermatol"},{"key":"1521_CR14","doi-asserted-by":"publisher","first-page":"e823","DOI":"10.1111\/jdv.19921","volume":"38","author":"C Ure\u00f1a-Paniego","year":"2024","unstructured":"Ure\u00f1a-Paniego C, Haselgruber S, Soto-Moreno A, Cuenca-Barrales C, Arias-Santiago S, Molina-Leyva A. Eligibility in a cohort of patients with hidradenitis suppurativa treated with bimekizumab: lessons and pitfalls in a real-world setting. J Eur Acad Dermatol Venereol. 2024;38:e823\u20134.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1521_CR15","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1111\/jdv.19725","volume":"38","author":"P Aarts","year":"2024","unstructured":"Aarts P, van Huijstee JC, van der Zee HH, van Straalen KR, Prens EP. Improved clinical effectiveness of adalimumab when initiated with clindamycin and rifampicin in hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2024;38:904\u20139.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1521_CR16","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.jaad.2023.04.034","volume":"89","author":"P Aarts","year":"2023","unstructured":"Aarts P, van Huijstee JC, van der Zee HH, van Doorn MBA, van Straalen KR, Prens EP. Adalimumab in conjunction with surgery compared with adalimumab monotherapy for hidradenitis suppurativa: a randomized controlled trial in a real-world setting. J Am Acad Dermatol. 2023;89:677\u201384.","journal-title":"J Am Acad Dermatol"},{"key":"1521_CR17","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1111\/jdv.20472","volume":"39","author":"CC Zouboulis","year":"2025","unstructured":"Zouboulis CC, Bechara FG, Benhadou F, et al. European S2k guidelines for hidradenitis suppurativa\/acne inversa part 2: treatment. J Eur Acad Dermatol Venereol. 2025;39:899\u2013941.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1521_CR18","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.ad.2024.12.018","volume":"116","author":"L Carnero Gonz\u00e1lez","year":"2025","unstructured":"Carnero Gonz\u00e1lez L, Garcias-Ladaria JG, Rivera-D\u00edaz R, et al. Spanish Hidradenitis Suppurativa Registry (REHS) of the Spanish academy of dermatology and venereology: description and data from its first year of operation. Actas Dermosifiliogr. 2025;116:567\u201374.","journal-title":"Actas Dermosifiliogr"},{"key":"1521_CR19","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1111\/bjd.15748","volume":"177","author":"CC Zouboulis","year":"2017","unstructured":"Zouboulis CC, Tzellos T, Kyrgidis A, et al. Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity. Br J Dermatol. 2017;177:1401\u20139.","journal-title":"Br J Dermatol"},{"key":"1521_CR20","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/jdv.18632","volume":"37","author":"T Tzellos","year":"2023","unstructured":"Tzellos T, van Straalen KR, Kyrgidis A, et al. Development and validation of IHS4-55, an IHS4 dichotomous outcome to assess treatment effect for hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2023;37:395\u2013401.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1521_CR21","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14254","volume":"33","author":"T Montero-Vilchez","year":"2020","unstructured":"Montero-Vilchez T, Salvador-Rodriguez L, Sanchez-Diaz M, et al. Clinical selection criteria in new clinical trials of hidradenitis suppurativa: external validity and implications on the daily clinical practice. Dermatol Ther. 2020;33:e14254.","journal-title":"Dermatol Ther"},{"key":"1521_CR22","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1111\/jdv.16183","volume":"34","author":"A Martorell","year":"2020","unstructured":"Martorell A, Jfri A, Koster SBL, et al. Defining hidradenitis suppurativa phenotypes based on the elementary lesion pattern: results of a prospective study. J Eur Acad Dermatol Venereol. 2020;34:1309\u201318.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1521_CR23","doi-asserted-by":"crossref","unstructured":"Mu\u00f1oz-Barba D, Haselgruber de Francisco S, Le\u00f3n-P\u00e9rez FJ, et al. Severity and therapeutic decisions based on lesion location in patients with hidradenitis suppurativa. Int J Dermatol. 2025;64(9):1607\u201314.","DOI":"10.1111\/ijd.17861"},{"key":"1521_CR24","doi-asserted-by":"crossref","unstructured":"12th EHSF Conference 2023 Extended Abstracts. Experimental Dermatology. 2023;32:9\u2013156.","DOI":"10.1111\/exd.14898"},{"key":"1521_CR25","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S0140-6736(23)00022-3","volume":"401","author":"AB Kimball","year":"2023","unstructured":"Kimball AB, Jemec GBE, Alavi A, et al. Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week\u00a016 and week\u00a052 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase\u00a03 trials. Lancet. 2023;401:747\u201361.","journal-title":"Lancet"},{"key":"1521_CR26","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.jaci.2023.05.012","volume":"152","author":"J Kim","year":"2023","unstructured":"Kim J, Lee J, Li X, et al. Single-cell transcriptomics suggest distinct upstream drivers of IL-17A\/F in hidradenitis versus psoriasis. J Allergy Clin Immunol. 2023;152:656\u201366.","journal-title":"J Allergy Clin Immunol"},{"key":"1521_CR27","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/j.jaci.2023.03.035","volume":"152","author":"S Cole","year":"2023","unstructured":"Cole S, Manghera A, Burns L, et al. Differential regulation of IL-17A and IL-17F via STAT5 contributes to psoriatic disease. J Allergy Clin Immunol. 2023;152:783\u201398.","journal-title":"J Allergy Clin Immunol"},{"key":"1521_CR28","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1093\/bjd\/ljae442","volume":"192","author":"J Rastrick","year":"2025","unstructured":"Rastrick J, Edwards H, Ferecsk\u00f3 AS, et al. The roles of interleukin (IL)-17A and IL-17F in hidradenitis suppurativa pathogenesis: evidence from human in vitro preclinical experiments and clinical samples. Br J Dermatol. 2025;192:660\u201371.","journal-title":"Br J Dermatol"},{"key":"1521_CR29","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1007\/s13555-024-01209-w","volume":"14","author":"S Haselgruber","year":"2024","unstructured":"Haselgruber S, Fern\u00e1ndez-Crehuet-Serrano P, Fern\u00e1ndez-Ballesteros MD, et al. Insights into the window of opportunity and outcome measures in patients with moderate to severe hidradenitis suppurativa treated with secukinumab: a real-world study. Dermatol Ther (Heidelb). 2024;14:1875\u201390.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1521_CR30","doi-asserted-by":"publisher","first-page":"3035","DOI":"10.1007\/s10620-019-05504-x","volume":"64","author":"C Le Berre","year":"2019","unstructured":"Le Berre C, Danese S, Peyrin-Biroulet L. Timely use of biologics in early Crohn\u2019s disease: the return of \u00abhit hard and early\u00bb? Dig Dis Sci. 2019;64:3035\u20137.","journal-title":"Dig Dis Sci"},{"key":"1521_CR31","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1056\/NEJMoa1504370","volume":"375","author":"AB Kimball","year":"2016","unstructured":"Kimball AB, Okun MM, Williams DA, et al. Two phase\u00a03 trials of adalimumab for hidradenitis suppurativa. N Engl J Med. 2016;375:422\u201334.","journal-title":"N Engl J Med"},{"key":"1521_CR32","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/j.jaad.2024.11.065","volume":"92","author":"MK Branyiczky","year":"2025","unstructured":"Branyiczky MK, Huang RS, Abu-Hilal M. Risk of Candida and overall fungal infections with interleukin-17 inhibitors in the treatment of hidradenitis suppurativa: a systematic review and meta-analysis. J Am Acad Dermatol. 2025;92:930\u20132.","journal-title":"J Am Acad Dermatol"},{"key":"1521_CR33","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.4049\/jimmunol.2400510","volume":"213","author":"L Dos Santos Dias","year":"2024","unstructured":"Dos Santos Dias L, Lionakis MS. IL-17: a critical cytokine for defense against oral candidiasis. J Immunol. 2024;213:1049\u201351.","journal-title":"J Immunol"},{"key":"1521_CR34","doi-asserted-by":"publisher","unstructured":"Berenguer-Ruiz S, Aparicio-Dom\u00ednguez M, Butr\u00f3n-Bris B, Dauden E, Llamas-Velasco M. Antifungal prophylaxis and effective therapy with bimekizumab in a patient with multiresistant plaque psoriasis and recurrent candidiasis. Int J Dermatol. 2025. https:\/\/doi.org\/10.1111\/ijd.17824.","DOI":"10.1111\/ijd.17824"},{"key":"1521_CR35","doi-asserted-by":"publisher","unstructured":"Al-Wattar-Ceballos O, Mart\u00ednez-Montalvo L, Carmona-Rodr\u00edguez M. Safety and efficacy profile of anti-IL17 treatments in hidradenitis suppurativa: systematic review and meta-analysis of randomized placebo-controlled trials. Actas Dermosifiliogr. 2025:S0001-7310(25)00362-X. https:\/\/doi.org\/10.1016\/j.ad.2024.12.027.","DOI":"10.1016\/j.ad.2024.12.027"},{"key":"1521_CR36","doi-asserted-by":"publisher","DOI":"10.1002\/ski2.371","volume":"4","author":"GM Falco","year":"2024","unstructured":"Falco GM, Caldarola G, D\u2019Amore A, Pinto LM, De Simone C, Peris K. Eczematous eruption during bimekizumab treatment in a psoriatic patient previously treated with secukinumab. Skin Health Dis. 2024;4:e371.","journal-title":"Skin Health Dis"},{"key":"1521_CR37","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1007\/s13555-025-01364-8","volume":"15","author":"F Martora","year":"2025","unstructured":"Martora F, Battista T, Potestio L, Megna M. Severe paradoxical scalp psoriasis induced by bimekizumab in a young multifailure hidradenitis suppurativa patient. Dermatol Ther (Heidelb). 2025;15:763\u20139.","journal-title":"Dermatol Ther (Heidelb)"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01521-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01521-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01521-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T17:17:37Z","timestamp":1761239857000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01521-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,27]]},"references-count":37,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["1521"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01521-z","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,27]]},"assertion":[{"value":"15 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Research Ethics Committee at the Hospital Universitario y Polit\u00e9cnico La Fe (Valencia, Spain) and was conducted in accordance with the Declaration of Helsinki on the ethical principles of medical research involving human subjects. Patients\u2019 names, initials, or hospital numbers were not used.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Alejandro Molina-Levya is an Editorial Board member of\n                      Dermatology and Therapy\n                      . Alejandro Molina-Levya was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Alejandro Molina-Leyva has received support for attending meetings, served as an advisory board member and participated in clinical trials from Abbvie, Novartis, Moonlake, MSD, Sanofi, Incyte Almirall and UCB. Eva Vilarrasa has received honoraria and\/or travel grants and\/or has served as an advisory board member and\/or has participated in clinical trials sponsored by Abbvie, Aceleryn, Almirall, Amgen, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Gebro, Incyte, Isdin, Janssen, Leo-Pharma, Lilly, Merck-Serono, MoonLake, MSD, Novartis, Pfizer, Roche, Sandoz, Sanofi, UCB. She also has worked as consultant or participated in clinical trials for iDermApp, Mediktor, DermUS, Biomi, HSCalc, BHH. Antonio Martorell has received honoraria and\/or travel grants and\/or has served as an advisory board member for Novartis, AbbVie, Janssen Cilag, UCB, Lilly, LEO Pharma, L\u2019Oreal, Sanofi, Boehringer Ingelheim, Almirall, Bristol Myers Squibb, and Amgen. Additionally, AM has worked as a principal investigator in clinical trials supported by AbbVie, UCB, Janssen, Bristol Myers Squibb, Lilly, Galderma, Sanofi, and Novartis. Miguel Mansilla-Polo has received honoraria and\/or travel grants and\/or has served as an advisory board member for Novartis, UCB, Almirall, Sunpharma. Pablo Fernandez-Crehuet, Alberto Soto-Moreno and Fernando Alfageme- Rold\u00e1n has received honoraria and\/or travel grants and\/or has served as an advisory board member for Novartis, Abbvie and UCB. Patricia Garbayo-Salmons declares honoraria for participating in advisory boards from Novartis and UCB; received support for attending meetings and\/or travel from AbbVie, Amgen, Lilly, LEO Pharma, Novartis and UCB. Carmen Garc\u00eda -Moronta received support from UCB and Novartis to attend scientific congresses. Laura Mahiques-Santos has received travel grants from Abbvie and has served as an advisory board member for Novartis. Irene S\u00e1nchez-Guti\u00e9rrez has received honoraria from Novartis and UCB. Gemma Mart\u00edn-Ezquerra has received honoraria and\/or travel grants from Novartis and has served as an advisory board member for UCB and Boehringer Ingelheim. Mart\u00ed Pons-Benavent has received honoraria from Abbvie and Almirall. Rafael Fayos-Gregori, David Jim\u00e9nez-Gallo, Luc\u00eda Aguilar-Gonz\u00e1lez and Bego\u00f1a Escutia-Mu\u00f1oz have nothing to disclose. Rebeca Alcala-Garc\u00eda has provided scientific advice and participated in medical meetings and training courses sponsored by Almirall, Ferrer, Leo Pharma, Janssen, Novartis, Pierre Fabre, UCB, and participated as a principal investigator or collaborator in clinical trials or research projects for UCB. Antonio Sahuquillo-Torralba has served as a consultant and\/or paid speaker for and\/or participated in clinical trials sponsored by companies that manufacture drugs used for the treatment of psoriasis, including AbbVie, Celgene, Janssen-Cilag, LEO Pharma, Lilly, Novartis and Pfizer. Rafael Botella-Estrada has served as a consultant and\/or paid speaker for and\/or participated in clinical trials sponsored by including AbbVie, Celgene, Janssen-Cilag, LEO, Pharma, Lilly, Novartis and Pfizer. Rafael Fayos-Gregori, David Jimenez-Gallo, Lucia Aguilar-Gonzalez and Bego\u00f1a Escutia-Mu\u00f1oz have nothing to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}